MCF Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

MCF Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-723	Closed	-$12.6K	–	1000
2025 Q2	$12.6K	Buy	+723	New	+$10.4K	﹤0.01%	614

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

MCF Advisors's SPRY Position: Q3 2025 in Review

MCF Advisors sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 723 shares — an estimated $12.6K sold.

MCF Advisors first reported a position in SPRY in Q2 2025 and held it in 1 quarter. The position peaked at $12.6K in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

MCF Advisors reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
MCF Advisors sold 723 ARS Pharmaceuticals shares in Q3 2025, an estimated $12.6K.
MCF Advisors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 1 quarter.
MCF Advisors's ARS Pharmaceuticals position peaked at $12.6K in Q2 2025.
188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on MCF Advisors's 13F filing for Q3 2025, filed 5 Nov 2025.